As I've posted on numerous occasions, Copaxone is a very much easier drug to characterize than Lovenox. If the FDA was willing to approve MNTA's generic Lovenox, MNTA's obtaining approval for generic Copaxone in due course is close to a fait accompli, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.